Neurocrine Biosciences, Inc. Stock Analysis & AI Score
Neurocrine Biosciences, Inc. (NBIX) has an ST Score of 50.3 (C+), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $203.82 price target (+46.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Neurocrine Biosciences, Inc. (NBIX) has an ST Score of 50.3 (C+), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $203.82 price target (+46.7% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- MomentumB
- GrowthB
- ForecastB
- Financial StrengthD-
- ValuationF
- Piotroski5/9
Contact
NBIX stock: frequently asked questions
What is NBIX's ST Score?
Neurocrine Biosciences, Inc. (NBIX) has an ST Score of 50.3 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NBIX a buy, hold, or sell?
Analysts rate NBIX a Buy, with a price target of $203.82 (+46.7% vs the current price). Our ST Score grades it C+ (50.3/100). The ST Score is a data-driven signal, not a recommendation.
What are NBIX's factor grades?
Valuation F, Profitability A+, Financial Strength D-, Momentum B, Growth B, Forecast B.
What is NBIX's valuation grade?
Neurocrine Biosciences, Inc. (NBIX) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NBIX's growth grade?
Neurocrine Biosciences, Inc. (NBIX) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NBIX's profitability grade?
Neurocrine Biosciences, Inc. (NBIX) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NBIX's financial strength grade?
Neurocrine Biosciences, Inc. (NBIX) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NBIX?
The average analyst price target for Neurocrine Biosciences, Inc. (NBIX) is $203.82 from 37 analysts, which is +46.7% versus the recent price of $138.94.
What is NBIX's Piotroski score?
Neurocrine Biosciences, Inc. (NBIX) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.